{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:35:19Z","timestamp":1794476119313,"version":"4.9.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Erosive esophagitis (EE) is a gastroesophageal reflux disease characterized by mucosal breaks in the esophagus. Proton pump inhibitors are widely used as maintenance therapy for EE, but many patients still relapse. In this trial, we evaluated the noninferiority of vonoprazan <jats:italic toggle=\"yes\">vs.<\/jats:italic> lansoprazole as maintenance therapy in patients with healed EE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We performed a double-blind, double-dummy, multicenter, phase 3 clinical trial among non-Japanese Asian adults with endoscopically confirmed healed EE from April 2015 to February 2019. Patients from China, South Korea, and Malaysia were randomized to vonoprazan 10\u00a0mg or 20\u00a0mg once daily or lansoprazole 15\u00a0mg once daily for 24 weeks. The primary endpoint was endoscopically confirmed EE recurrence rate over 24 weeks with a noninferiority margin of 10% using a two-sided 95% confidence interval (CI). Treatment-emergent adverse events (TEAEs) were recorded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among 703 patients, EE recurrence was observed in 24\/181 (13.3%) and 21\/171 (12.3%) patients receiving vonoprazan 10\u00a0mg or 20\u00a0mg, respectively, and 47\/184 (25.5%) patients receiving lansoprazole (differences: \u201312.3% [95% CI, \u201320.3% to \u20134.3%] and \u201313.3% [95% CI, \u201321.3% to \u20135.3%], respectively), meeting the primary endpoint of noninferiority to lansoprazole in preventing EE recurrence at 24 weeks. Evidence of superiority (upper bound of 95% CI &lt;0%) was also observed. At 12 weeks, endoscopically confirmed EE recurrence was observed in 5\/18, 2\/20, and 7\/20 of patients receiving vonoprazan 10\u00a0mg, vonoprazan 20\u00a0mg, and lansoprazole, respectively. TEAEs were experienced by 66.8% (157\/235), 69.0% (156\/226), and 65.3% (158\/242) of patients receiving vonoprazan 10\u00a0mg, vonoprazan 20\u00a0mg, and lansoprazole, respectively. The most common TEAE was upper respiratory tract infection in 12.8% (30\/235) and 12.8% (29\/226) patients in vonoprazan 10 mg and 20 mg groups, respectively and 8.7% (21\/242) patients in lansoprazole group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Vonoprazan maintenance therapy was well-tolerated and noninferior to lansoprazole for preventing EE recurrence in Asian patients with healed EE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial Registration:<\/jats:title>\n            <jats:p>\n                                 https:\/\/clinicaltrials.gov; NCT02388737.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003068","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T04:00:58Z","timestamp":1713931258000},"page":"962-971","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Vonoprazan 10\u00a0mg or 20\u00a0mg vs. lansoprazole 15\u00a0mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial"],"prefix":"10.1097","volume":"137","author":[{"given":"Yinglian","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510062, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine Zhejiang University, Hangzhou, Zhejiang 310020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon Jai","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengtang","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan 33353, China"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan 33353, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chui Fung","family":"Chong","sequence":"additional","affiliation":[{"name":"Takeda Development Center Asia, Singapore 018981, Singapore"},{"name":"Current affiliation: Hoffmann-La Roche, Basel, 4070 Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Funao","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company, Chuo-ku, Osaka 540-8645, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuichi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company, Chuo-ku, Osaka 540-8645, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica D.","family":"Eisner","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Company, Cambridge, MA, 02142 USA"},{"name":"Current affiliation: Abbott Laboratories, Lake Forest, IL 60045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[{"name":"China Medical Team, Takeda China, Beijing 100027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510062, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","article-title":"Presentation and epidemiology of gastroesophageal reflux disease","volume":"154","author":"Richter","year":"2018","journal-title":"Gastroenterology"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","article-title":"Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: A meta-analysis","volume":"67","author":"Eusebi","year":"2018","journal-title":"Gut"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015","volume":"51","author":"Iwakiri","year":"2016","journal-title":"J Gastroenterol"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1136\/gutjnl-2016-311715","article-title":"Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: An update focusing on refractory reflux disease and Barrett\u2019s oesophagus","volume":"65","author":"Fock","year":"2016","journal-title":"Gut"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"78","DOI":"10.14740\/gr753w","article-title":"Correlation between symptom severity and health-related life quality of a population with gastroesophageal reflux disease","volume":"10","author":"Lee","year":"2017","journal-title":"Gastroenterology Res"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1477-7525-8-128","article-title":"Impact of gastroesophageal reflux disease on daily life: The Systematic Investigation of Gastrointestinal Diseases in China (SILC) epidemiological study","volume":"8","author":"Wang","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/j.1365-2036.2010.04471.x","article-title":"Meta-analysis: The association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux","volume":"32","author":"Rubenstein","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5056\/jnm.2014.20.1.6","article-title":"New and future drug development for gastroesophageal reflux disease","volume":"20","author":"Maradey-Romero","year":"2014","journal-title":"J Neurogastroenterol Motil"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","article-title":"Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis","volume":"112","author":"Chiba","year":"1997","journal-title":"Gastroenterology"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5056\/jnm15105","article-title":"Unmet needs in the treatment of gastroesophageal reflux disease","volume":"21","author":"Dickman","year":"2015","journal-title":"J Neurogastroenterol Motil"},{"key":"R11-20250602","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases\u2013A position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"Scarpignato","year":"2016","journal-title":"BMC Med"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11938-018-0206-y","article-title":"Potent acid suppression with PPIs and P-CABs: What\u2019s new?","volume":"16","author":"Hunt","year":"2018","journal-title":"Curr Treat Options Gastroenterol"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.111.185314","article-title":"Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438)","volume":"339","author":"Shin","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5056\/jnm18029","article-title":"Potent potassium-competitive acid blockers: A new era for the treatment of acid-related diseases","volume":"24","author":"Oshima","year":"2018","journal-title":"J Neurogastroenterol Motil"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","article-title":"Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis","volume":"69","author":"Xiao","year":"2020","journal-title":"Gut"},{"key":"R17-20250602","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3748\/wjg.v24.i14.1550","article-title":"Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole","volume":"24","author":"Ashida","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R18-20250602","first-page":"1865","article-title":"Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)","volume":"58","author":"Endo","year":"2000","journal-title":"Nihon Rinsho"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/1751-2980.12676","article-title":"Effect of high-fat, standard, and functional food meals on esophageal and gastric pH in patients with gastroesophageal reflux disease and healthy subjects","volume":"19","author":"Fan","year":"2018","journal-title":"J Dig Dis"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.3390\/nu7064661","article-title":"The difference in nutrient intakes between Chinese and Mediterranean, Japanese and American diets","volume":"7","author":"Zhang","year":"2015","journal-title":"Nutrients"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s00535-017-1417-z","article-title":"Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: The Japan-based EXTEND study","volume":"53","author":"Kinoshita","year":"2018","journal-title":"J Gastroenterol"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000500399","article-title":"Efficacy of vonoprazan for 48-week maintenance therapy of patients with healed reflux esophagitis","volume":"101","author":"Mizuno","year":"2020","journal-title":"Digestion"},{"key":"R23-20250602","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13876","article-title":"Randomised clinical trial: Efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers\u2013Results from two phase 3, non-inferiority randomised controlled trials","volume":"45","author":"Miwa","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1016\/S0016-5085(19)37576-6","article-title":"Sa1194: 1-year interim analysis results of VISION TRIAL: A randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis","volume":"156","author":"Uemura","year":"2019","journal-title":"Gastroenterology"},{"key":"R25-20250602","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF02774209","article-title":"Serum pepsinogens as a screening test of extensive chronic gastritis","volume":"22","author":"Miki","year":"1987","journal-title":"Gastroenterol Jpn"},{"key":"R26-20250602","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype","volume":"43","author":"Kagami","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R27-20250602","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MCG.0000000000000854","article-title":"World gastroenterology organisation global guidelines: GERD global perspective on gastroesophageal reflux disease","volume":"51","author":"Hunt","year":"2017","journal-title":"J Clin Gastroenterol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:07:44Z","timestamp":1748891264000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003068","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]},"assertion":[{"value":"2023-06-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}